Bamlanivimab Reduces Risk Of COVID-19 Infection: JAMA Study
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Bamlanivimab therapy reduced the risk of COVID-19 in residents and staff of skilled nursing and assisted living facilities, according to a study published in the Journal of American Medical Association.

Healthcare workers are at high risk for developing SARS-CoV-2 as close living environments, presymptomatic transmission and frequent staff contact with frail residents contribute to the infection. Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody may confer rapid protection from Sars-Cov-2 infection.

The investigators carried out a randomised clinical trial to determine the effect of bamlanivimab on the incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities. The study was a randomized, double-blind, single-dose, phase 3 trial that included a total of 1175 participants between August 2 to November 20, 2020.

There was at least 1 confirmed SARS-CoV-2 index case and participants were randomized to receive a single intravenous infusion of bamlanivimab, 4200 mg (n=588), or placebo (n=587). The primary outcome was incidence of COVID-19 infection and mild or worse disease severity within 21 days of detection, within 8 weeks of randomization. Secondary outcomes included incidence of moderate or worse COVID-19 severity and incidence of SARS-CoV-2 infection.

According to the results of the study,

~ Bamlanivimab significantly reduced the incidence of COVID-19 in the prevention population compared with placebo.

~ Five deaths attributed to COVID-19 were reported by day 57; all occurred in the placebo group.

~ Reported adverse events was 20.1% in the bamlanivimab group and 18.9% in the placebo group. The most common adverse events were urinary tract infection.

The trial clearly demonstrates that among residents and staff in skilled nursing and assisted living facilities, bamlanivimab monotherapy reduced the incidence of COVID-19 infection, suggesting the potential of bamlanivimab as a preventive intervention.

"Further research is needed to assess preventive efficacy with current patterns of viral strains with combination monoclonal antibody therapy," the investigators concluded.

Source:
https://jamanetwork.com/journals/jama/fullarticle/2780870
Dr. T●●●●z H●●●●●●i and 1 others like this4 shares
Like
Comment
Share